Trials / Completed
CompletedNCT04345471
A Study of MD-120 in Patients With Depression
A Placebo-controlled Study of MD-120 in Patients With Depression
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 615 (actual)
- Sponsor
- Mochida Pharmaceutical Company, Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to verify the efficacy and evaluate the safety of 8-week once-daily oral administration of MD-120 in Japanese patients with depression.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desvenlafaxine 100 mg | once daily dosing for 8 weeks |
| DRUG | Desvenlafaxine 50 mg | once daily dosing for 8 weeks |
| DRUG | Placebo | once daily dosing for 8 weeks |
Timeline
- Start date
- 2020-05-18
- Primary completion
- 2022-07-21
- Completion
- 2022-09-14
- First posted
- 2020-04-14
- Last updated
- 2024-02-29
- Results posted
- 2024-02-29
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04345471. Inclusion in this directory is not an endorsement.